Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

ALGN · Q4 2025 Earnings

Align Technology

Reported February 4, 2026

30-second summary

30-second take: Q4 revenue of $1.048B (+5.3% YoY) beat the $1,025–1,045M guide and Clear Aligner shipments grew +7.7% YoY to 676.9K cases — the cleanest volume print in years and confirmation that Q3's re-acceleration was not a fluke. Management finally bridged the 2026 math: revenue +3–4% YoY with ~400bps of GAAP operating margin improvement (to slightly below 18.0%) and +100bps non-GAAP (to ~23.7%), built on restructuring savings rather than top-line leverage. The volume story is working; the FY26 revenue range lands below the 5–15% LRP floor, and management's "cautiously optimistic" framing concedes that margin expansion has to do most of the work.

Headline numbers

EPS

Q4 FY2025

$3.29

Revenue

Q4 FY2025

$1.05B

+5.3% YoY

Gross margin

Q4 FY2025

65.3%

Operating margin

Q4 FY2025

14.8%

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$1.05B	+5.3%	$1.00B	+5.3%
EPS	$3.29	—	$2.61	+26.1%
Gross margin	65.3%	—	64.2%	+110bps
Operating margin	14.8%	—	9.7%	+510bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q4 FY2025	$1,025M to $1,045M	$1,048M	+$3M above guide (at high end, +0.3%)	Beat
GAAP Gross Margin	Q4 FY2025	65.5% to 66.0%	65.3%	-0.2% to -0.7% below guide	Beat
Non-GAAP Gross Margin	Q4 FY2025	Approximately 71.0%	72.0%	+1.0% above guidance (100bps beat)	Met
GAAP Operating Margin	Q4 FY2025	15.3% to 15.8%	14.8%	-0.5% to -1.0% below guide	Beat
Non-GAAP Operating Margin	Q4 FY2025	Approximately 26.0%	26.1%	+0.1% above guidance (10bps beat)	Met
Worldwide Revenue Growth	FY 2025	Flat to slightly up from 2024	0.9% YoY	+0.9% YoY (below qualitative 'flat to slightly up' expectation, which implied 0-2%)	Missed
GAAP Operating Margin	FY 2025	Around 13.6% to 13.8%	13.5%	-0.1% to -0.3% below guide	Met
Non-GAAP Operating Margin	FY 2025	Slightly above 22.5%	~22.6% implied	in-line	Met

New guidance

Metric	Period	Guide	YoY
Worldwide Revenue Growth	FY 2026	3% to 4% YoY	—
Clear Aligner Volume Growth	FY 2026	Mid-single digits YoY	—
GAAP Operating Margin	FY 2026	Slightly below 18.0% (approx 400bps improvement YoY)	—

Segment KPIs

Q4 FY2025

Segment	Q4 FY2025	YoY
Clear Aligner	$0.838B	+5.5%
Imaging Systems and CAD/CAM Services	$0.209B	+4.2%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Clear Aligner Case Shipments	676.9 thousand cases
Clear Aligner Case Shipments YoY Growth	+7.7%
Clear Aligner Case Shipments QoQ Growth	+4.5%
Invisalign Trained Doctors	87.7 thousand submitters in Q4 (record for Q4)
Active iTero Scanner Units	Over 121 thousand
Clear Aligner Revenue Per Case Shipment	$1,240
Non-GAAP Gross Margin	72.0%
Non-GAAP Operating Margin	26.1%

Management tone

Q2 restructuring pivot → Q3 cautious stabilization → Q4 cautious optimism with execution attribution.

The growth attribution has shifted from market to internal levers across three quarters. Q2 framed weakness as macro-driven; Q3 framed stabilization as "team executing better"; Q4 explicitly grounds confidence in operational actions rather than market recovery: "Our confidence is grounded in the actions we're taking to actively manage the business and drive growth through our core strategic priorities." The signal: management does not expect the orthodontic category to bail them out, and the FY26 +3–4% revenue guide reflects that — well below the 5–15% LRP floor, telegraphing that the LRP is aspirational until further notice.

DSO has moved from "a channel" to "the channel." Q2 mentioned DSO strength in passing; Q3 highlighted 20%+ growth in pockets of North America DSO; this quarter Joe Hogan called out DSOs as "one of Align's most important and scalable strategic growth channels," with top-10 Americas DSOs growing double digits YoY, North America DSO performance up double digits led by adult, and EMEA DSOs delivering double-digit growth with triple-digit growth among the top-10 EMEA DSOs. The structural read: retail doctor weakness in North America is not reversing, and Align's strategic response is to lean harder into the channel that is winning at the retail doctor's expense. Hogan's framing — "practices taking an active approach to conversion, scanning every patient, using chair-side visualization tools and offering patient financing are performing better than those that don't" — is essentially a concession that the product alone is not the moat anymore; workflow adoption is.

The adult segment surprise reframes the FY26 setup. Across Q2 and Q3, the adult patient cohort was the bear case — macro-pressured, financing-constrained, and the source of North America retail weakness. This quarter the press release disclosed adult patient volumes +8% YoY in Q4, and Joe Hogan attributed the strength to DSO penetration, portfolio breadth, and HFD financing. If adult holds, the FY26 +3–4% guide is conservative; if it relapses, the guide is exposed. Management did not commit to adult durability — the cautious-optimism framing is exactly the right hedge.

Direct fabrication margin trajectory got more concrete. Prior quarters left direct fab as a vague future capability. This quarter Joe Hogan acknowledged that "early production has some dilutive margin impact until scale," with limited market release of Invisalign First direct 3D printed retainers and Invisalign-specific 3D printed prefab attachments in 2026, and more complex products expected to follow in 2027. That dilution is why the FY26 non-GAAP operating margin guide is only +100bps despite the ~+400bps GAAP improvement — direct fab and tariff headwinds eat the operational savings on a non-GAAP basis.

China VBP downgraded from material risk to neutral. Q2 and Q3 flagged VBP as a contingent overhang. Q4 explicitly excludes VBP impact from guidance and frames Align as 85%+ private in China and well-positioned via local manufacturing and a China-specific portfolio — i.e., insulated. If that read is wrong, the FY26 guide has a hole; if right, one tail risk is closed.

Recurring themes management leaned on this quarter:

DSO channel acceleration as primary growth lever across all regionsAdult patient segment re-acceleration driven by financing, visualization tools, and portfolio flexibilityInternational expansion momentum (EMEA, Latin America, APAC) offsetting North America softnessEarly intervention products (Invisalign First, Pallet Expander, MAOB) driving teen/kids growth trajectoryMargin expansion through operational efficiency and product mix shift toward no-refinement offeringsDigital ecosystem integration (Invisalign, iTero, ExoCAD) as competitive moat and GP engagement path

Risks management surfaced:

China VBP implementation timeline and pricing impact remains uncertain despite status quo assumptionNorth America macro consumer sentiment and patient inflow pressured in retail channelDirect fabrication margin dilution in 2026 until scale achieved in 2027-2028Foreign exchange volatility impacting sequential and year-over-year resultsU.S. tariff impacts and broader macroeconomic conditions subject to change beyond management control

Answers to last quarter's watch list

Q4 ASP actually reversing the QoQ decline. ASP came in at $1,240, down another $5 QoQ from $1,245 — directly opposite to the guided sequential increase on favorable geographic mix. The "geographic rotation" thesis from Q3 did not hold; YoY price erosion (-$25) looks structural.

Resolved negatively

Q4 revenue vs $1,025–1,045M. Revenue of $1.048B beat the top of the range by $3M, with shipments accelerating to +7.7% YoY (676.9K cases) doing all the work against the still-falling ASP. Volume re-acceleration is now confirmed.

Resolved positively

North America retail showing any improvement in gross receipts or CCA. Management characterized North America as "more stability" with retail "not as negative" — improvement at the margin but not a turn. The structural diagnosis from Q3 stands; DSO is masking retail rot, just slightly less so.

Continue monitoring

2026 revenue framing on the Q4 call. Management delivered: +3–4% YoY revenue, mid-single digit Clear Aligner volume, ~400bps GAAP operating margin improvement to slightly below 18.0%, and ~100bps non-GAAP improvement to ~23.7%. The top-line range lands below the 5–15% LRP floor, which is the cleanest possible signal that the LRP is aspirational. Status: Resolved negatively (range below LRP).

Clear Aligner volume holding mid-single digits in Q4. Shipments hit 676.9K cases (+7.7% YoY, +4.5% QoQ), above the ~660K threshold and accelerating from Q3. The FY guide raise is fully validated.

Resolved positively

Restructuring final charge tally and FY26 cost-out attribution. Q4 incurred $67.5M of restructuring and accelerated depreciation charges; FY25 restructuring and other charges totaled ~$42.9M (cash) plus ~$157.9M of non-cash items including impairments. The ~400bps GAAP margin improvement comes mostly from absence of those FY25 charges plus operational savings, while non-GAAP at +100bps shows the underlying operational lift is modest.

Continue monitoring

What to watch into next quarter

Q1 ASP actually printing up sequentially. Guidance again calls for ASP up on favorable geographic mix. Q4 missed the same guide. A second consecutive QoQ decline would make "geographic mix tailwind" a discredited talking point and force a structural pricing conversation.

Q1 revenue tracking inside $1,010–1,030M. Implies +3–5% YoY; a miss on the low end would put the FY26 +3–4% guide at risk in the first quarter of the year.

Adult segment growth sustaining mid-single digits or better. Q4's ~8% adult growth was the upside surprise; if Q1 prints back at low-single digits, the FY26 guide loses its most credible top-line lever.

DSO penetration continuing to outpace retail. Top-10 Americas DSOs are growing double digits and top-10 EMEA DSOs triple digits while retail stays flat — if that divergence widens, the company increasingly becomes a B2B distribution story rather than a consumer-led growth story, relevant for both margin durability and valuation framework.

First disclosure of direct fab margin drag quantified. Management said dilutive until scale, with limited market release in 2026 and more complex products in 2027. Watch for an explicit basis-point drag figure to separate underlying operational margin progress from the capex-cycle headwind.

China revenue trajectory absent VBP impact. Guide assumes status quo; any disclosure that VBP is broadening beyond the public hospital system or moving against Align's 85%+ private-sector mix would force a re-rate of the FY26 setup.

Sources

Align Technology Q4 2025 earnings press release, February 4, 2026 — https://www.sec.gov/Archives/edgar/data/1097149/000109714926000006/algn-q425earningspressrele.htm
Align Technology Q4 2025 earnings call transcript (prepared remarks and Q&A)
Align Technology Q3 2025 earnings press release and call (prior guidance baseline)
Align Technology Q2 2025 earnings press release (restructuring program baseline)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.